Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10498112 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL37475 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234790 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233046 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL236969 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL231824 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2036043 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL24563 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Colfosceril Palmitate SCHEMBL2734250 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632413-B1 | LONG-CIRCULATING LIPOSOME MODIFIED WITH C(RGD-ACP-K) | BEIJING GREATSUN BIO PHARM TECH CO LTD (CN) | 2024-09-11 | — | — | EP | claimed |
| CN-118178324-A | FAP alpha hydrolysis charge-turned liposome and composition, and preparation method and application thereof | 锐康九域(厦门)医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118027094-A | Lipid compound or derivative thereof and pharmaceutical composition comprising same | 财团法人工业技术研究院 | 2024-05-14 | — | — | CN | claimed |
| WO-2023096511-A1 | DRUG LIPID CARRIER, PHARMACEUTICAL FORMULATION, USES THEREOF AND METHOD FOR PREPARATION OF DRUG LIPID CARRIER, CARRIER OBTAINED BY THIS METHOD AND USES THEREOF | UNIWERSYTET WARSZAWSKI (PL) | 2023-06-01 | — | — | WO | claimed |
| EP-4727949-A1 | POLYMORPHS AND THEIR USE FOR TREATING CANCER | Cairn Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719497-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | Rayzebio, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4705440-A1 | NAMPT FUSION PROTEINS | Monash University (AU) | 2026-03-11 | — | — | EP | disclosed |
| US-20260021161-A1 | SILK PEPTIDES TOPICAL FORMULATIONS AND METHODS OF THEIR USE | SILKLYFE INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4658313-A1 | HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF | GENZYME CORPORATION (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | 2A BIOSCIENCES, INC. | 2025-11-20 | — | — | US | disclosed |
| WO-2025029805-A2 | HEMOSTATIC COMPOSITIONS AND METHODS | PMIDG, LLC (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025024400-A2 | SUBSTITUTED TRYPTAMINES AND USES THEREOF | 2A BIOSCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2001075170-A1 | A FUNCTIONAL ASSAY OF HIGH-DENSITY LIPOPROTEIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0726761-B1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOMED INC (US) | 2001-01-10 | — | — | EP | disclosed |
| US-5858398-A | MICROPARTICLES CONTAINING ACTIVE AGENT, MIXTURE OF PHOSPHOLIPIDS, MIXTURE OF NONIONIC SURFACTANTS, STEROL SUSPENDED IN FATTY ACID | ISOMED INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0521994-B1 | PHARMACEUTICAL FORMULATIONS | SKUA INVESTMENTS LTD (GB) | 1997-06-18 | — | — | EP | disclosed |
| EP-0726761-A1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOTECH MEDICAL, INC. (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012385-A1 | MICROPARTICULAR PHARMACEUTICAL COMPOSITIONS IN MICELLAR FORM | ISOTECH MEDICAL, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| EP-0521994-A1 | PHARMACEUTICAL FORMULATIONS. | SKUA INVESTMENTS LTD (GB) | 1993-01-13 | — | — | EP | disclosed |
| WO-1991014454-A1 | PHARMACEUTICAL FORMULATIONS | SKUA INVESTMENTS LIMITED (GB) | 1991-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021161-A1 | SILK PEPTIDES TOPICAL FORMULATIONS AND METHODS OF THEIR USE | CUTA, APP, ITCH | SMN1; SMN2 607/4885NR5A2 4316/4885NR5A1 3087/4885 |
| US-20250353808-A1 | 5-METHOXYMETHYL AND 5-HYDROXYMETHYL PHENETHYLAMINES | HTR5A, PNMT, HTR6 | SMN1; SMN2 2702/4885NR5A2 213/4885NR5A1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.